UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma is a funding opportunity from UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, up to 547212, closing August 31, 2026.
Aug 31, 2026
(31d left)Overview
Glioblastoma (GBM) is the most common and most aggressive of the primary malignant brain tumor in adults, with a median overall survival of 19.6 months following multi-modality therapy. The main limiting factor in delivering a tumoricidal radiation dose is the toxicity to surrounding brain. Therapeutic radionuclides,…